Truveris Appoints Nanette Oddo President and Chief Executive Officer
Truveris has announced that Nanette Oddo has been named president and chief executive officer. A veteran industry leader, Oddo previously served as Truveris’ chief strategy officer, spearheading the company’s strategic vision during a period of consistent innovation and growth.
“Truveris uniquely bends the cost curve to improve the accessibility and affordability of prescription medications, one of the critical challenges facing healthcare today,” Oddo said. “Through our industry-leading information and marketplace solutions, Truveris challenges the status quo to offer prescription savings and better prescription access for our extraordinary clients, their employees, and patients. I am honored to work with our team to meet the growing needs in this rapidly changing industry.”
Oddo has been an innovator and leader at several high-growth organizations. Prior to Truveris, Oddo spent 12 years in various leadership roles at Phreesia, the leading intake and patient engagement solution. As Phreesia’s general manager, Oddo played a key role in the company’s explosive growth. Previously, Oddo held senior roles at TNS Healthcare (now KantarHealth) and Pharmetrics (now IMS). She has also served in a variety of leadership positions in managed care, data analytics, and patient engagement at companies such as CVS Caremark and Medco.
“Through her career, Nanette has successfully scaled several high-growth healthcare and pharmacy companies,” said Canaan General Partner and Truveris board member Stephen M. Bloch, MD. “She possesses an unwavering commitment to clients, driven by a desire to leverage technology to reduce complexity and improve the healthcare experience. The board looks forward to helping Nanette propel Truveris’ growth.”
Truveris is focused on delivering truth and clarity in pharmacy. The company’s proprietary technology, coupled with deep pharmacy expertise, helps to build a more efficient market that maximizes choice, accessibility, and prescription drug affordability.
Read the full press release here.